Hyseq Appoints Two Top Executives: Senior Vice President and Chief Financial Officer, Peter S. Garcia and Senior Vice President of Human Resources, Linda A. Fitzpatrick

Apr 25, 2001, 01:00 ET from Hyseq, Inc.

    SUNNYVALE, Calif., April 25 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ)
 Hyseq Inc. today announced that Peter S. Garcia will join Hyseq as Senior Vice
 President and Chief Financial Officer, and Linda A. Fitzpatrick joins as
 Senior Vice President of Human Resources.  "Linda and Pete are both world-
 class, and I am thrilled that they will add significantly to the quality of
 our management team at Hyseq.  This is an important period for Hyseq as we are
 adding key players to the team and gather momentum heading into the next phase
 of the company's growth.  Pete and Linda bring impressive backgrounds to their
 respective areas and we expect them to be an integral part of the company's
 new culture and business plan," said Ted W. Love, M.D., Hyseq's President and
 CEO.
     "I am thrilled to be joining the Hyseq team led by George Rathmann and Ted
 Love, and I think its going to be a very exciting story at Hyseq as we move
 toward becoming a leading biopharmaceutical and life science company," said
 Mr. Garcia.  Mr. Garcia brings five years of experience as a Chief Financial
 Officer in emerging life science companies, including Novacept, Inc.,
 IntraBiotics Pharmaceuticals, Inc., and Dendreon Corporation.  Prior to this
 experience, Mr. Garcia worked at Amgen Inc. for six years in a variety of
 financial executive positions including Assistant Corporate Controller.  Mr.
 Garcia graduated with honors with a Bachelor of Arts degree in Economics and
 Sociology from Stanford University, and earned his Master of Business
 Administration from the University of California at Los Angeles.  Mr. Garcia
 currently serves on the Board of Directors of Morphogen Pharmaceuticals, Inc.
 of San Diego, California.
     "I'm excited by the challenges and growth that Hyseq faces, and feel I can
 contribute to help turn Hyseq into a highly successful company," said Ms.
 Fitzpatrick.  Ms. Fitzpatrick comes to Hyseq from Advanced Medicine, Inc. of
 South San Francisco, California, where she served as Senior Advisor.  Ms.
 Fitzpatrick brings seven years experience in senior roles in the Human
 Resources, Corporate Communications and Operations departments at Gilead
 Sciences, Inc. of Foster City, California.  Prior to her tenure at Gilead
 Sciences, Ms. Fitzpatrick served eight years at Genentech in South San
 Francisco, California where her positions included Director, Investor
 Relations and Director, Compensation, Benefits and Systems.  Ms. Fitzpatrick
 graduated with honors with a Bachelor of Science degree in Sociology and
 Psychology from San Francisco State University.
     Hyseq is researching and developing biopharmaceutical products from its
 collection of novel genes discovered using its proprietary high-throughput
 technology.  Hyseq has collaborations for discovering gene-based products and
 for commercializing its biochip.  Information about Hyseq is available at
 www.hyseq.com or by phoning (408) 524-8100.
 
     Statements included in this press release which are not historical in
 nature, are intended to be, and are hereby identified as "forward-looking
 statements" for purposes of the safe harbor provided by the Private Securities
 Litigation Act of 1995.  Forward looking statements may be identified by words
 such as "believe," "expect," "anticipate," "should," "may," "estimated" and
 "potential," among others.  The Company cautions readers that forward-looking
 statements, including without limitation, those relating to the Company's
 future business prospects are subject to certain risks and uncertainties that
 could cause actual results to differ materially from those indicated in the
 forward-looking statements.  For a discussion of factors that may cause
 results to differ, see the Company's reports filed with the SEC, including its
 Annual Report on Form 10-K for the year ended December 31, 2000.  Hyseq
 disclaims any intent or obligation to update these forward-looking statements.
 
     Contact:
      Dawn Nakao
      Investor Relations Manager
      Hyseq, Inc.
      408-524-8100
 
      Hershel Berry or Lee Stern (Investors)
      The Trout Group
      415-567-3300
      212-477-9007
 
      Andy Cutler or Amy Bergstrom (Media)
      Feinstein Kean Healthcare
      617-577-8110
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X34920238
 
 

SOURCE Hyseq, Inc.
    SUNNYVALE, Calif., April 25 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ)
 Hyseq Inc. today announced that Peter S. Garcia will join Hyseq as Senior Vice
 President and Chief Financial Officer, and Linda A. Fitzpatrick joins as
 Senior Vice President of Human Resources.  "Linda and Pete are both world-
 class, and I am thrilled that they will add significantly to the quality of
 our management team at Hyseq.  This is an important period for Hyseq as we are
 adding key players to the team and gather momentum heading into the next phase
 of the company's growth.  Pete and Linda bring impressive backgrounds to their
 respective areas and we expect them to be an integral part of the company's
 new culture and business plan," said Ted W. Love, M.D., Hyseq's President and
 CEO.
     "I am thrilled to be joining the Hyseq team led by George Rathmann and Ted
 Love, and I think its going to be a very exciting story at Hyseq as we move
 toward becoming a leading biopharmaceutical and life science company," said
 Mr. Garcia.  Mr. Garcia brings five years of experience as a Chief Financial
 Officer in emerging life science companies, including Novacept, Inc.,
 IntraBiotics Pharmaceuticals, Inc., and Dendreon Corporation.  Prior to this
 experience, Mr. Garcia worked at Amgen Inc. for six years in a variety of
 financial executive positions including Assistant Corporate Controller.  Mr.
 Garcia graduated with honors with a Bachelor of Arts degree in Economics and
 Sociology from Stanford University, and earned his Master of Business
 Administration from the University of California at Los Angeles.  Mr. Garcia
 currently serves on the Board of Directors of Morphogen Pharmaceuticals, Inc.
 of San Diego, California.
     "I'm excited by the challenges and growth that Hyseq faces, and feel I can
 contribute to help turn Hyseq into a highly successful company," said Ms.
 Fitzpatrick.  Ms. Fitzpatrick comes to Hyseq from Advanced Medicine, Inc. of
 South San Francisco, California, where she served as Senior Advisor.  Ms.
 Fitzpatrick brings seven years experience in senior roles in the Human
 Resources, Corporate Communications and Operations departments at Gilead
 Sciences, Inc. of Foster City, California.  Prior to her tenure at Gilead
 Sciences, Ms. Fitzpatrick served eight years at Genentech in South San
 Francisco, California where her positions included Director, Investor
 Relations and Director, Compensation, Benefits and Systems.  Ms. Fitzpatrick
 graduated with honors with a Bachelor of Science degree in Sociology and
 Psychology from San Francisco State University.
     Hyseq is researching and developing biopharmaceutical products from its
 collection of novel genes discovered using its proprietary high-throughput
 technology.  Hyseq has collaborations for discovering gene-based products and
 for commercializing its biochip.  Information about Hyseq is available at
 www.hyseq.com or by phoning (408) 524-8100.
 
     Statements included in this press release which are not historical in
 nature, are intended to be, and are hereby identified as "forward-looking
 statements" for purposes of the safe harbor provided by the Private Securities
 Litigation Act of 1995.  Forward looking statements may be identified by words
 such as "believe," "expect," "anticipate," "should," "may," "estimated" and
 "potential," among others.  The Company cautions readers that forward-looking
 statements, including without limitation, those relating to the Company's
 future business prospects are subject to certain risks and uncertainties that
 could cause actual results to differ materially from those indicated in the
 forward-looking statements.  For a discussion of factors that may cause
 results to differ, see the Company's reports filed with the SEC, including its
 Annual Report on Form 10-K for the year ended December 31, 2000.  Hyseq
 disclaims any intent or obligation to update these forward-looking statements.
 
     Contact:
      Dawn Nakao
      Investor Relations Manager
      Hyseq, Inc.
      408-524-8100
 
      Hershel Berry or Lee Stern (Investors)
      The Trout Group
      415-567-3300
      212-477-9007
 
      Andy Cutler or Amy Bergstrom (Media)
      Feinstein Kean Healthcare
      617-577-8110
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X34920238
 
 SOURCE  Hyseq, Inc.